The Wall Avenue Journal with the report
The Novavax vaccine, it says, presents key doable benefits over its opponents:
- early knowledge counsel the Novavax shot could also be one of many first proven to stem asymptomatic unfold of the coronavirus
- and in addition probably present longer-lasting safety
Its a 2 shot vaccine. Approval nonetheless seems a few months away.
An attention-grabbing learn however the agency has clearly misplaced first-mover benefit and by the point it will get approval, then into distribution, it would properly be too late?